ClinicalTrials.gg
RecruitingNCT06887387Updated Nov 19, 2026

Wearable Devices for Patient Monitoring in Long QT Syndrome

An observational study in Long QT Syndrome, sponsored by Queen Mary University of London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Queen Mary University of London · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Nov 19, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years and older
Sex
All
01

Study summary

The main research question of this study is whether wearable devices have utility in monitoring patients with Long QT syndrome.

02

Conditions studied

  • Long QT Syndrome

Browse trials for

03

In context

Long QT Syndrome

101 studies on the registry are indexed under Long QT Syndrome; 20 are open to participants now.

This study's planned enrollment of 80 is below the median of 150 across 53 observational studies indexed under Long QT Syndrome.

Browse Long QT Syndrome studies →

Lead sponsor

Queen Mary University of London is the lead sponsor of 253 studies on the registry; 58 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with a diagnosis of long QT syndrome

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of Long Syndrome
  • Aged 18 years or over
  • Phone with iOS version 15 or Android OS 9.0 or higher
  • Able and willing to provide

Exclusion criteria

Exclusion Criteria:

  • Unwilling or unable to give consent
  • Ventricular pacing at recruitment
  • Bundle branch block or pre-excitation at baseline
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes

Interventions

  • DeviceWearable device

    This is an observational study that does not impact routine clinical care for participants

06

What researchers measure

Primary outcomes

  1. 1. Determine the accuracy of repeated QT interval measurements using Fitbit-derived ECGs in patients with Long QT syndrome compared with the current standard (12-lead ECG and ambulatory monitors)

    Time frame: From enrollment to 3 months

  2. 2. Establish intra-patient QT variability from weekly Fitbit-ECGs and frequency of measurements over 500ms.

    Time frame: From enrollment to 3 months

Secondary outcomes

  1. 1. Establish the utility of wearable devices for determining symptom aetiology in LQTS.

    Time frame: From enrollment to 3 months

  2. 2. Develop pipelines for the analysis of ECG data collected remotely including use of in-house QT automated algorithms for future machine learning applications.

    Time frame: From enrollment to 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Sep 2027, 29 months after the start.

Of 21 observational studies under Long QT Syndrome, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 81. This study's planned 29 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Sep 2026 → Sep 2027 and completion Sep 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2025
First posted
Mar 20, 2025
StartActual
Apr 1, 2025
Primary completionEst.
Sep 4, 2027was Sep 2026
CompletionEst.
Sep 4, 2027was Sep 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 4, 2026→Sep 4, 2027
Nov 19, 2026
Study completion
Sep 4, 2026→Sep 4, 2027
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Primary completion Sep 4, 2026→Sep 4, 2027
    Study completion Sep 4, 2026→Sep 4, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06887387
Responsible party
Sponsor
First posted
Mar 20, 2025
Start date
Apr 1, 2025
Primary completion
Sep 4, 2027 (estimated)
Completion
Sep 4, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

William J Young, MBBS, PhD
principal investigator · Queen Mary University of London and St Bartholomew's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion